ATE317264T1 - Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose - Google Patents

Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose

Info

Publication number
ATE317264T1
ATE317264T1 AT97949680T AT97949680T ATE317264T1 AT E317264 T1 ATE317264 T1 AT E317264T1 AT 97949680 T AT97949680 T AT 97949680T AT 97949680 T AT97949680 T AT 97949680T AT E317264 T1 ATE317264 T1 AT E317264T1
Authority
AT
Austria
Prior art keywords
atherosclerosis
methods
low density
density lipoprotein
binding proteins
Prior art date
Application number
AT97949680T
Other languages
English (en)
Inventor
Ann M Lees
Robert S Lees
Simon W Law
Anibal A Arjona
Original Assignee
Boston Heart Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Heart Foundation Inc filed Critical Boston Heart Foundation Inc
Application granted granted Critical
Publication of ATE317264T1 publication Critical patent/ATE317264T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
AT97949680T 1996-11-27 1997-11-26 Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose ATE317264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3193096P 1996-11-27 1996-11-27
US4854797P 1997-06-03 1997-06-03

Publications (1)

Publication Number Publication Date
ATE317264T1 true ATE317264T1 (de) 2006-02-15

Family

ID=26707786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949680T ATE317264T1 (de) 1996-11-27 1997-11-26 Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose

Country Status (10)

Country Link
US (2) US6355451B1 (de)
EP (1) EP0969855B1 (de)
JP (1) JP4184437B2 (de)
AT (1) ATE317264T1 (de)
AU (1) AU736142B2 (de)
CA (1) CA2272243A1 (de)
DE (1) DE69735243T2 (de)
ES (1) ES2258798T3 (de)
IL (1) IL129910A0 (de)
WO (1) WO1998023282A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632923B1 (en) * 1996-11-27 2003-10-14 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US6605588B1 (en) 1996-11-27 2003-08-12 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
WO2002102250A1 (en) * 1999-10-22 2002-12-27 Glaxo Group Limited $g(in vivo) imaging
CN1329142A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——rna聚合酶ii相关蛋白11.33和编码这种多肽的多核苷酸
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
US20060032508A1 (en) * 2000-12-20 2006-02-16 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
EP3434276B1 (de) 2012-06-06 2024-10-30 Pepkon Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von krebs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59206046A (ja) * 1983-05-11 1984-11-21 Asahi Chem Ind Co Ltd 低比重リポ蛋白質を吸着する材料
US4660563A (en) 1984-12-31 1987-04-28 Massachusetts Institute Of Technology Method and means for detection of arterial lesions
US4877599A (en) 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5726153A (en) 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5135848A (en) 1989-10-23 1992-08-04 Lehigh University And Northeast Benjamin Franklin Technology Center Of Pa Methods for evaluating cholesterol metabolism and reagents therefor
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
JPH05507276A (ja) 1990-05-03 1993-10-21 ニュー・イングランド・ディーコネス・ホスピタル・コーポレイション 動脈造影用合成ペプチド類
DE4222385A1 (de) 1992-07-08 1994-01-13 Boehringer Ingelheim Int Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors
EP0586094A1 (de) 1992-08-03 1994-03-09 Wisconsin Alumni Research Foundation Löslicher LDL-Rezeptor und Gen
AU6234194A (en) 1993-01-15 1994-08-15 Board Of Regents, The University Of Texas System High molecular weight b-cell growth factor: interleukin-14
JPH09163988A (ja) 1995-10-09 1997-06-24 Kowa Co 新規なｌｄｌ受容体類似蛋白質及び遺伝子

Also Published As

Publication number Publication date
DE69735243D1 (de) 2006-04-20
WO1998023282A1 (en) 1998-06-04
EP0969855B1 (de) 2006-02-08
US20020052033A1 (en) 2002-05-02
AU736142B2 (en) 2001-07-26
JP2001506983A (ja) 2001-05-29
JP4184437B2 (ja) 2008-11-19
DE69735243T2 (de) 2006-11-02
IL129910A0 (en) 2000-02-29
AU7408898A (en) 1998-06-22
ES2258798T3 (es) 2006-09-01
US6355451B1 (en) 2002-03-12
CA2272243A1 (en) 1998-06-04
EP0969855A4 (de) 2001-08-16
EP0969855A1 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
Murphy et al. Identity and polymerization-stimulatory activity of the nontubulin proteins associated with microtubules
ATE458051T1 (de) Low density lipoprotein-bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose
Vallee et al. Removal of the projections from cytoplasmic microtubules in vitro by digestion with trypsin.
Ripamonti et al. Long‐term evaluation of bone formation by osteogenic protein 1 in the baboon and relative efficacy of bone‐derived bone morphogenetic proteins delivered by irradiated xenogeneic collagenous matrices
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
EA200100502A1 (ru) СПОСОБЫ И КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ КОНФОРМАЦИОННОЙ СТАБИЛЬНОСТИ БЕЛКА СЕМЕЙСТВА p53
DE69535703D1 (de) Aav-vermittelte überbringung von dna in zellen des nervensystems
Collen et al. Postreceptor modulation of action of VIP and secretin on pancreatic enzyme secretion by secretagogues that mobilize cellular calcium
PT98113A (pt) Processo para a preparacao de proteinas de fusao com uma fraccao de imunoglobulina
ATE317264T1 (de) Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose
Maestracci et al. Proteins and glycoproteins of the human intestinal brush border membrane
Wilson et al. Proteomic analysis of cartilage proteins
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
DE69836963D1 (de) PGC-1, EIN NEUARTIGER PPAR-gamma-KOAKTIVATOR AUS BRAUNEM FETTGEWEBE
Feit et al. Identification of a protein related to tubulin in the postsynaptic density.
Bab et al. Isolation of mitogenically active C‐terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells
Nishimoto et al. The vitamin K-dependent bone protein is accumulated within cultured osteosarcoma cells in the presence of the vitamin K antagonist warfarin.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
Vittur et al. The calcium binding properties of a glycoprotein isolated from pre-osseous cartilage
Oemrawsingh et al. Isolation, purification and chemical characterization of mucins from human submandibular glands
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
DE69533485D1 (de) Neue polypeptide
DE10080849D2 (de) Fragmente des Virus Proteins 2 oder 3 des Polymavirus als Fähren für Wirkstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties